相关实验视频

Updated: Jul 20, 2025

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

反应性氧物种-响应性聚合物原药纳米颗粒用于选择性和有效治疗炎症疾病

Yaming Zhang¹, Lu Liu¹, Tianyi Wang¹

¹State Key Laboratory of Pharmaceutical Biotechnology & Dr. Li Dak-Sum Research Centre & Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

Advanced healthcare materials

|August 4, 2023

概括

新的反应性氧物种响应纳米颗粒 (ROS-CA-NP) 为炎症性疾病提供了改善的治疗方法. 这些新型纳米疗法显示出增强的疗效和生物相容性,克服了传统抗炎药物的局限性.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
药理学药理学是指药理学的学科.

背景情况:

传统的抗炎药物有效性有限,由于选择性,稳定性和溶解性差,会引起全身副作用.
管理类风湿性关节炎和性结肠炎等炎症性疾病仍然是一个重大的临床挑战.

研究的目的:

开发一种新的纳米粒子系统,ROS-CA-NP,对反应性氧物种 (ROS) 产生反应,用于向药物输送.
在炎症性疾病的临床前模型中评估ROS-CA-NP的治疗疗效和生物相容性.

主要方法:

使用聚合物-甲 (CA) 联合物合成ROS-CA-NP.
评估药物稳定性,组织选择性和在氧化应激时的受控释放.
在风湿性关节炎和性结肠炎的小鼠模型中评估治疗疗效和生物相容性.

主要成果:

ROS-CA-NP表现出卓越的药物稳定性,组织选择性和受氧化应激激活的受控释放.
与传统药物相比,ROS-CA-NP的全身治疗导致了炎症病变的积累和更高的治疗疗效.
在测试模型中,ROS-CA-NP表现出极好的生物相容性.

结论:

ROS-CA-NP代表了一种有前途的纳米治疗平台,用于治疗炎症疾病.
这些纳米颗粒的ROS反应性质增强了向炎症组织的药物输送.
这种新的系统为传统的抗炎治疗提供了更安全,更有效的替代方案.

关键词:

对ROS有反应的纳米粒子.cinnamaldehyde 的使用方法聚合物前药物聚合物前药物类风湿性关节炎类风湿性关节炎性结肠炎是一种

更多相关视频

Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo

Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo

Published on: February 5, 2019

Electroactive Polymer Nanoparticles Exhibiting Photothermal Properties

Electroactive Polymer Nanoparticles Exhibiting Photothermal Properties

Published on: January 8, 2016

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Inflammatory Response

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...